Yi Wu, Ana Werlang, Weiwei Cheng, Andrea Lanes, Shi Wu Wen, Mark Walker
{"title":"细胞游离 DNA 总含量与先兆子痫发生之间的关系--文献综述。","authors":"Yi Wu, Ana Werlang, Weiwei Cheng, Andrea Lanes, Shi Wu Wen, Mark Walker","doi":"10.1055/s-0040-1721674","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives</b> The aim of the study is to synthesize the evidence and evaluate the total cell-free deoxyribonucleic (cfDNA) associated with the prediction of preeclampsia (PE). Total cfDNA is constituted by both cell-free fetal DNA (cffDNA) originated mainly from the placenta, and maternal cfDNA derived from maternal leukocytes. <b>Methods</b> A systematic review was conducted by searching PubMed and Medline. Literature reporting levels of total cfDNA in the development of PE was included. Studies that only reported cffDNA, but no cfDNA concentrations were not included in this review. <b>Results</b> Eight studies were included. Seven reported values of cfDNA in PE patients, regardless of early or late onset PE, six of which demonstrated a significant increase of cfDNA in patients who subsequently developed PE. Seven studies evaluated cfDNA levels in the first trimester, six of which showed significant increase of cfDNA concentrations in women who later developed PE. Five studies investigated cfDNA levels in the second trimester, all presenting increased total cfDNA levels in the PE group compared with normal controls. <b>Conclusion</b> Total cfDNA may play a role as a biochemical marker of PE, compared with fetal cfDNA. Large prospective studies with homogeneous populations and standardized methodology are needed to further confirm its predictive value.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"11 1","pages":"e38-e48"},"PeriodicalIF":0.8000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/c8/10-1055-s-0040-1721674.PMC7964254.pdf","citationCount":"0","resultStr":"{\"title\":\"Association between Levels of Total Cell-Free DNA and Development of Preeclampsia-A Literature Review.\",\"authors\":\"Yi Wu, Ana Werlang, Weiwei Cheng, Andrea Lanes, Shi Wu Wen, Mark Walker\",\"doi\":\"10.1055/s-0040-1721674\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objectives</b> The aim of the study is to synthesize the evidence and evaluate the total cell-free deoxyribonucleic (cfDNA) associated with the prediction of preeclampsia (PE). Total cfDNA is constituted by both cell-free fetal DNA (cffDNA) originated mainly from the placenta, and maternal cfDNA derived from maternal leukocytes. <b>Methods</b> A systematic review was conducted by searching PubMed and Medline. Literature reporting levels of total cfDNA in the development of PE was included. Studies that only reported cffDNA, but no cfDNA concentrations were not included in this review. <b>Results</b> Eight studies were included. Seven reported values of cfDNA in PE patients, regardless of early or late onset PE, six of which demonstrated a significant increase of cfDNA in patients who subsequently developed PE. Seven studies evaluated cfDNA levels in the first trimester, six of which showed significant increase of cfDNA concentrations in women who later developed PE. Five studies investigated cfDNA levels in the second trimester, all presenting increased total cfDNA levels in the PE group compared with normal controls. <b>Conclusion</b> Total cfDNA may play a role as a biochemical marker of PE, compared with fetal cfDNA. Large prospective studies with homogeneous populations and standardized methodology are needed to further confirm its predictive value.</p>\",\"PeriodicalId\":7645,\"journal\":{\"name\":\"AJP Reports\",\"volume\":\"11 1\",\"pages\":\"e38-e48\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/c8/10-1055-s-0040-1721674.PMC7964254.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AJP Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0040-1721674\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/3/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJP Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0040-1721674","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
摘要
目的 本研究旨在总结证据,评估与子痫前期(PE)预测相关的无细胞脱氧核糖核酸(cfDNA)总量。总的无细胞脱氧核糖核酸(cfDNA)由主要来自胎盘的胎儿无细胞脱氧核糖核酸(cffDNA)和来自母体白细胞的母体无细胞脱氧核糖核酸(cfDNA)构成。方法 通过搜索 PubMed 和 Medline 进行了系统性综述。纳入了报告在 PE 发病过程中总 cfDNA 水平的文献。仅报告 cffDNA 而未报告 cfDNA 浓度的研究未纳入本综述。结果 共纳入八项研究。其中 7 项研究报告了 PE 患者的 cfDNA 值,无论患者是早期还是晚期发病,其中 6 项研究表明,在随后发展为 PE 的患者中,cfDNA 有显著增加。七项研究对妊娠头三个月的 cfDNA 水平进行了评估,其中六项研究显示,后来患上 PE 的妇女体内的 cfDNA 浓度明显增加。五项研究调查了妊娠后三个月的 cfDNA 水平,与正常对照组相比,所有研究均显示 PE 组的 cfDNA 总含量有所增加。结论 与胎儿 cfDNA 相比,cfDNA 总含量可能是 PE 的生化标志物。为进一步证实其预测价值,需要对同质人群和标准化方法进行大型前瞻性研究。
Association between Levels of Total Cell-Free DNA and Development of Preeclampsia-A Literature Review.
Objectives The aim of the study is to synthesize the evidence and evaluate the total cell-free deoxyribonucleic (cfDNA) associated with the prediction of preeclampsia (PE). Total cfDNA is constituted by both cell-free fetal DNA (cffDNA) originated mainly from the placenta, and maternal cfDNA derived from maternal leukocytes. Methods A systematic review was conducted by searching PubMed and Medline. Literature reporting levels of total cfDNA in the development of PE was included. Studies that only reported cffDNA, but no cfDNA concentrations were not included in this review. Results Eight studies were included. Seven reported values of cfDNA in PE patients, regardless of early or late onset PE, six of which demonstrated a significant increase of cfDNA in patients who subsequently developed PE. Seven studies evaluated cfDNA levels in the first trimester, six of which showed significant increase of cfDNA concentrations in women who later developed PE. Five studies investigated cfDNA levels in the second trimester, all presenting increased total cfDNA levels in the PE group compared with normal controls. Conclusion Total cfDNA may play a role as a biochemical marker of PE, compared with fetal cfDNA. Large prospective studies with homogeneous populations and standardized methodology are needed to further confirm its predictive value.